SGI-110 to potentiate platinum response: a phase Ib/randomised IIa open label clinical trial combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer.
Phase of Trial: Phase I/II
Latest Information Update: 10 Apr 2018
At a glance
- Drugs Guadecitabine (Primary) ; Cisplatin; Gemcitabine
- Indications Bladder cancer; Solid tumours
- Focus Adverse reactions
- Acronyms SPIRE
- 08 Mar 2016 Status changed from not yet recruiting to recruiting, as reported by ISRCTN: Current Controlled Trials.
- 03 Feb 2016 New trial record